Skip to content

To access the new portal/member content, please reset your username and password by clicking "I forgot my login name or password" on this page.

Pediatric Endocrine Society
  • Clinical
    Resources
    • Clinical Resource Library
    • Referral Guidelines
    • Special Interest Groups
    • Online Community
    • Insurance Appeal Letter Templates
    • And the survey says…
  • Patient
    Resources
    • What is a Pediatric Endocrinologist?
    • Patient Education
      • Patient Education Videos
    • Find a Pediatric Endocrinologist
    • Camps
    • Clinical Studies
    • Transition Toolkit
  • Education
    & Events
    • PES 50th Anniversary
    • Events Calendar
    • PES 2023 Annual Meeting
    • Board Review Course
    • Online Education
    • PES Leadership Advantage (PESLA)
    • Mentor Match Program
    • Fellows, Residents, and Students
      • PedsENDO365
      • PedsENDO Discovery Program
      • Practical Clinical Tools
      • Clinical Update and Case Discussion Course
      • Spring Fellows Retreat
      • ESPE E-Learning Web Portal
      • Mentoring Program
      • SEED
  • News &
    Publications
    • PES News & Announcements
    • Journal
  • Careers
    • Job Board
    • Pediatric Endocrine Program Directors
    • Certification
      • Maintenance of Certification (MOC)
      • Ethics in Pediatric Endocrinology MOC
      • PES Obesity SIG MOC/CME Activity
      • Precocious Puberty Self-Assessment MOC/CME
  • Grants
    & Awards
    • Senior Awards and Lectureships
    • Fellows and Junior Faculty Awards
    • Grants
  • About
    PES
    • About PES
      • Contact
      • Leadership
      • PES Committees
      • Society History
    • PES Membership
      • Join PES
    • Partner with Us
      • Mission Alliance Partners
      • Become a Mission Alliance Partner
      • PES Mission Alliance Partner Spotlight
      • Exhibit & Sponsorship Opportunities
      • Mailing List and Advertising
      • Conflict of Interest Statement
    • Policies and Strategy
      • Equity, Diversity and Inclusion Initiative
      • Strategic Plan
      • Policies and Bylaws
      • Public Policy and Advocacy
  • Join PES
  • Contact
  • Find a Pediatric Endocrinologist
  • Join PES
  • Contact
  • Find a Pediatric Endocrinologist
Pediatric Endocrine Society
Member Login
  • Clinical
    Resources
    • Clinical Resource Library
    • Referral Guidelines
    • Special Interest Groups
    • Online Community
    • Insurance Appeal Letter Templates
    • And the survey says…
  • Patient
    Resources
    • What is a Pediatric Endocrinologist?
    • Patient Education
      • Patient Education Videos
    • Find a Pediatric Endocrinologist
    • Camps
    • Clinical Studies
    • Transition Toolkit
  • Education
    & Events
    • PES 50th Anniversary
    • Events Calendar
    • PES 2023 Annual Meeting
    • Board Review Course
    • Online Education
    • PES Leadership Advantage (PESLA)
    • Mentor Match Program
    • Fellows, Residents, and Students
      • PedsENDO365
      • PedsENDO Discovery Program
      • Practical Clinical Tools
      • Clinical Update and Case Discussion Course
      • Spring Fellows Retreat
      • ESPE E-Learning Web Portal
      • Mentoring Program
      • SEED
  • News &
    Publications
    • PES News & Announcements
    • Journal
  • Careers
    • Job Board
    • Pediatric Endocrine Program Directors
    • Certification
      • Maintenance of Certification (MOC)
      • Ethics in Pediatric Endocrinology MOC
      • PES Obesity SIG MOC/CME Activity
      • Precocious Puberty Self-Assessment MOC/CME
  • Grants
    & Awards
    • Senior Awards and Lectureships
    • Fellows and Junior Faculty Awards
    • Grants
  • About
    PES
    • About PES
      • Contact
      • Leadership
      • PES Committees
      • Society History
    • PES Membership
      • Join PES
    • Partner with Us
      • Mission Alliance Partners
      • Become a Mission Alliance Partner
      • PES Mission Alliance Partner Spotlight
      • Exhibit & Sponsorship Opportunities
      • Mailing List and Advertising
      • Conflict of Interest Statement
    • Policies and Strategy
      • Equity, Diversity and Inclusion Initiative
      • Strategic Plan
      • Policies and Bylaws
      • Public Policy and Advocacy
  • Join PES
  • Contact
  • Find a Pediatric Endocrinologist
March 3, 2023

New Drugs and Therapeutics Update: Wegovy®

Wegovy® (semaglutide) once weekly injection is a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved by the FDA in June, 2021 for weight management in adults. Wegovy was approved in December, 2022 for children aged 12 and up with a BMI at the 95th% or above. This approval directly preceded the release of the first comprehensive guidelines on the evaluation and treatment of childhood obesity by the American Academy of Pediatrics (AAP).

Approval in pediatrics was based on a pivotal phase 3 trial published in The New England Journal of Medicine. Nearly 200 adolescents 12-18 years of age with a BMI of 95th% and higher or with a BMI of the 85th% or higher and at least one weight-related comorbid condition were enrolled. All participants completed a 12-week lifestyle intervention phase before randomization to once-weekly semaglutide (marching up to a dose of 2.4mg) or placebo. Most patients (90%) in the semaglutide group completed the trial, and the vast majority (87%) tolerated the highest dose.

The estimated mean percentage change in BMI from baseline to week 68, the endpoint of the trial, was 16.1% with semaglutide and 0.6% with placebo. Seventy-three percent of participants in the semaglutide group lost at least 5% of their body weight, compared to just 18% of the placebo group. A loss of body weight of at least 10% occurred in 62% of the participants in the semaglutide group, compared to 8% of placebo group, and a loss of at least 20% occurred in 37% and 3%, respectively.  Improvement in metabolic risk factors such as waist circumference, ALT, A1C, and total cholesterol were greater amongst treatment group than placebo group. Gastrointestinal side effects, such as nausea, vomiting, and diarrhea were more common in semaglutide than placebo (62% vs. 42%) but were generally mild to moderate, and peaked during or shortly after the 16-week dose escalation period.  Five participants (4%) in the semaglutide group had acute gallbladder disease while this did not occur in the placebo group. An increase in amylase and lipase levels were seen in the semaglutide group; however, there were no cases of pancreatitis observed. Serious adverse events were reported in 15 of 133 semaglutide participants (11%) and in 6 of 67 participants (9%) in the placebo group. There was an improvement in weight-related quality of life, mostly due to an improved physical comfort domain score. Interestingly, weight loss percentage was greater in the adolescent population in this trial than was reported in the Step1 trial in adults, potentially due to higher treatment completion rates in the trial.

The starting dose for Wegovy is 0.25 mg subcutaneous once weekly. The weekly dose is increased monthly until reaching the final dose of 2.4 mg – the dose is 0.5 mg for the second month, 1 mg for the third month, 1.7 mg for the fourth month, then 2.4 mg. Wegovy is contraindicated and should not be used in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Reference:

Weghuber D, Barrett T, Barrientos-Pérez M, et al for the STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022 Dec 15;387(24):2245-2257. PMID: 36322838.

Prepared by Emily Breidbart, MD, on behalf of the Drug & Therapeutics committee

Up to date as of 2/10/23

Posted in New Meds and Tech
Share this

Recent Posts

  • March 2023 President’s Letter
  • Historical Tidbit: Philip Showalter Hench, MD (February 28, 1896-March 30, 1965)
  • March Fellow Spotlight – Annie Gladding
  • March APP Spotlight – Kim Clash, CPNP
  • New Meds and Tech from the PES Drugs and Therapeutics committee: Dexcom G7

Categories

  • APP Spotlight
  • Drug Alerts/Recalls
  • Drug Shortages
  • Fellow Spotlight
  • Fellowship Posting
  • Historical Tidbits
  • In Memoriam
  • Member Spotlight
  • New Meds and Tech
  • News & Announcements
  • Oral History
  • PES Leadership Advantage
  • pm-pearls
  • President's Message
  • Public Policy
  • Student Spotlight
  • Uncategorized

Get Involved

Join a Special Interest Group

Learn More

Join PES

Learn More

Mentoring Program

Learn More

Explore PES Grants & Scholarships

Learn More

pes-white-logo

6728 Old McLean Village Dr
McLean, Virginia 22101
Phone: (703) 884-9781
info@pedsendo.org

  • Clinical
    Resources
    • Clinical Resource Library
    • Referral Guidelines
    • Special Interest Groups
    • Online Community
    • Insurance Appeal Letter Templates
    • And the survey says…
  • Patient
    Resources
    • What is a Pediatric Endocrinologist?
    • Patient Education
      • Patient Education Videos
    • Find a Pediatric Endocrinologist
    • Camps
    • Clinical Studies
    • Transition Toolkit
  • Education
    & Events
    • PES 50th Anniversary
    • Events Calendar
    • PES 2023 Annual Meeting
    • Board Review Course
    • Online Education
    • PES Leadership Advantage (PESLA)
    • Mentor Match Program
    • Fellows, Residents, and Students
      • PedsENDO365
      • PedsENDO Discovery Program
      • Practical Clinical Tools
      • Clinical Update and Case Discussion Course
      • Spring Fellows Retreat
      • ESPE E-Learning Web Portal
      • Mentoring Program
      • SEED
  • News &
    Publications
    • PES News & Announcements
    • Journal
  • Careers
    • Job Board
    • Pediatric Endocrine Program Directors
    • Certification
      • Maintenance of Certification (MOC)
      • Ethics in Pediatric Endocrinology MOC
      • PES Obesity SIG MOC/CME Activity
      • Precocious Puberty Self-Assessment MOC/CME
  • Grants
    & Awards
    • Senior Awards and Lectureships
    • Fellows and Junior Faculty Awards
    • Grants
  • About
    PES
    • About PES
      • Contact
      • Leadership
      • PES Committees
      • Society History
    • PES Membership
      • Join PES
    • Partner with Us
      • Mission Alliance Partners
      • Become a Mission Alliance Partner
      • PES Mission Alliance Partner Spotlight
      • Exhibit & Sponsorship Opportunities
      • Mailing List and Advertising
      • Conflict of Interest Statement
    • Policies and Strategy
      • Equity, Diversity and Inclusion Initiative
      • Strategic Plan
      • Policies and Bylaws
      • Public Policy and Advocacy
  • Join PES
  • Contact
  • Find a Pediatric Endocrinologist
  • Contact
  • Join PES

Learn More About PES!

Contact Us

© 2023 Pediatric Endocrine Society     Privacy Policy     Accessibility Statement

Website by Yoko Co

Scroll To Top